Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
Procarboxypeptidase U (TAFI) is a recently discovered plasma procarboxypeptidase that upon activation by thrombin or thrombin-thrombomodulin turns into a potent antifibrinolytic enzyme. Its prominent bridging function between coagulation and fibrinolysis raised the interest of many research groups and of the pharmaceutical industry. The development of carboxypeptidase U (CPU) inhibitors as profibrinolytic agents is an attractive concept and possibilities for rational drug design will become more readily available in the near future as a result of the recently published crystal structure. Numerous studies have been performed and many of them show beneficial effects of CPU inhibitors for the improvement of endogenous fibrinolysis in different animal sepsis and thrombosis models. CPU inhibitors combined with tissue-type plasminogen activator (t-PA) seem to increase the efficiency of pharmacological thrombolysis allowing lower dosing of t-PA and subsequently fewer bleeding complications. This review will focus on recently obtained in vivo data and the benefits/risks of targeting CPU for the treatment of thrombotic disorders.
Willemse
J L
JL
Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium.
Heylen
E
E
Nesheim
M E
ME
Hendriks
D F
DF
D025901:Carboxypeptidase B2 / Q000037:antagonists & inhibitors* / Q000502:physiology; D016503:Drug Delivery Systems / Q000379:methods*; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy
D025901:Carboxypeptidase B2